Academic Journal
Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg negative chronic hepatitis B
| العنوان: | Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg negative chronic hepatitis B |
|---|---|
| المؤلفون: | Kranidioti, Hara, Manolakopoulos, Spilios, Kontos, George, Breen, Michael, Kourikou, Anastasia, Deutsch, Melanie, Quesada del Bosque, Maria Ester, Martinez Nunez, Rocio T., Naiyer, Mohammed, Woelk, Christopher, Sanchez-Elsner, Tilman, Hadziyannis, Emilia, Papatheodoridis , George, Khakoo, Salim |
| المصدر: | Kranidioti , H , Manolakopoulos , S , Kontos , G , Breen , M , Kourikou , A , Deutsch , M , Quesada del Bosque , M E , Martinez Nunez , R T , Naiyer , M , Woelk , C , Sanchez-Elsner , T , Hadziyannis , E , Papatheodoridis , G & Khakoo , S 2019 , ' Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg negative chronic hepatitis B ' , Journal of Viral Hepatitis , vol. 26 , no. 6 , pp. 697-709 . .... |
| سنة النشر: | 2019 |
| المجموعة: | King's College, London: Research Portal |
| مصطلحات موضوعية: | chronic hepatitis B, nucleos(t)ide analogues, treatment discontinuation |
| الوصف: | The optimal duration of treatment with nucleos(t)ide analogues (NAs) for patients with HBeAg-negative Chronic Hepatitis B (CHB) is unknown. The aim of this study was to identify an immune signature associated with off-treatment remission to NA therapy. We performed microarray analysis of PBMCs from six patients with chronic hepatitis B who stopped NA therapy (3 with off-treatment remission, 3 with relapse) and 5 patients with chronic HBV infection (previously termed "inactive carriers") served as controls. Results were validated using qRT-PCR on a second group of 21 individuals (17 patients who stopped treatment and 4 controls). PBMCs from 38 patients on long-term NA treatment were analysed for potential to stop treatment. Microarray analysis indicated that patients with off-treatment remission segregated as a distinct out-group. Twenty-one genes were selected for subsequent validation. Ten of these were expressed at significantly lower levels in the patients with off-treatment remission compared to the patients with relapse and predicted remission with AUC of 0.78-0.92. IFNγ, IL-8, FASLG and CCL4 were the most significant by logistic regression. Twelve (31.6%) of 38 patients on long-term NA therapy had expression levels of all these four genes below cut-off values, and hence were candidates for stopping treatment. Our data suggest that patients with HBeAg-negative CHB who remain in off-treatment remission 3 years after NA cessation have a distinct immune signature and that PBMC RNA levels of IFNγ, IL-8, FASLG and CCL4 may serve as potential biomarkers for stopping NA therapy. This article is protected by copyright. All rights reserved. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| Relation: | https://kclpure.kcl.ac.uk/portal/en/publications/2c17100d-ab20-4c19-b6d3-dde9d6815d31 |
| DOI: | 10.1111/jvh.13068 |
| الاتاحة: | https://kclpure.kcl.ac.uk/portal/en/publications/2c17100d-ab20-4c19-b6d3-dde9d6815d31 https://doi.org/10.1111/jvh.13068 https://kclpure.kcl.ac.uk/ws/files/110561984/Immunological_biomarkers_as_indicators_KRANIDIOTI_Accepted9January2019_GREEN_AAM.pdf http://www.scopus.com/inward/record.url?scp=85062325889&partnerID=8YFLogxK |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.AED9856C |
| قاعدة البيانات: | BASE |
| DOI: | 10.1111/jvh.13068 |
|---|